Insmed vs Sarepta Therapeutics
INSM and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSM and SRPT compare
Insmed is the larger company, worth 16 times as much as Sarepta Therapeutics ($26.6B against $1.7B).
Insmed grew revenue faster over the last twelve months (240% versus −18.9% for Sarepta Therapeutics).
Sarepta Therapeutics keeps more of each dollar of sales as profit, with a net margin of −5.9% compared with −39.9% at Insmed.
Sarepta Therapeutics scores higher on the StockData Score (11 against 8 for Insmed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSM | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $26.6B | $1.7B |
| Share price | $121.16 | $16.07 |
| Change, 1 year | −37.7% | −10.7% |
| Change, 5 years | 298% | −79.9% |
| Beta (5Y) | 0.76 | 0.99 |
| Employees | 1,664 | 835 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 17.5× | 0.9× (better) |
| P/B | 36.6× | 1.1× (better) |
| P/FCF | – | 9.6× |
| FCF yield | −2.4% | 10.4% (better) |
| Fair value | $60.58 | $104.78 |
| Margin of safety | −100% | 84.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 240% (better) | −18.9% |
| Revenue growth, 5Y average | 29.8% | 32.4% (better) |
| Profitability | ||
| Gross margin | 84.4% | – |
| Operating margin | −37.1% | −2.5% (better) |
| Net margin | −39.9% | −5.9% (better) |
| FCF margin | −41.3% | 9.0% (better) |
| Return on equity | −72.5% | −7.6% (better) |
| Return on invested capital | – | −5.3% |
| Financial health | ||
| Debt / equity | 0.76 | 0.10 (better) |
| Interest coverage | −6.9× | – |
| Current ratio | 2.86 | 3.46 (better) |
| Altman Z-score | 7.36 (better) | −0.22 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 102% |
| Held by insiders | 0.89% | 5.9% |
| Insider net buying, 12 months | −$133M | −$417K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.5% | 19.4% |
Go deeper
- INSM stock overview
- INSM income statement
- INSM valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.